IN2014DN07019A - - Google Patents

Info

Publication number
IN2014DN07019A
IN2014DN07019A IN7019DEN2014A IN2014DN07019A IN 2014DN07019 A IN2014DN07019 A IN 2014DN07019A IN 7019DEN2014 A IN7019DEN2014 A IN 7019DEN2014A IN 2014DN07019 A IN2014DN07019 A IN 2014DN07019A
Authority
IN
India
Prior art keywords
positive
methods
cancer
mammalian subject
diagnosing
Prior art date
Application number
Inventor
Hans Peter Gerber
Dena Marrinucci
Shepherd Steven Pirie
Eric Tucker
Original Assignee
Pfizer
Epic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Epic Sciences Inc filed Critical Pfizer
Publication of IN2014DN07019A publication Critical patent/IN2014DN07019A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods are provided for detecting 5T4 positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4 positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4 positive metastatic cancer or early stage 5T4 positive cancer.
IN7019DEN2014 2012-01-24 2013-01-22 IN2014DN07019A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590066P 2012-01-24 2012-01-24
US201361753665P 2013-01-17 2013-01-17
PCT/IB2013/050547 WO2013111054A1 (en) 2012-01-24 2013-01-22 Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject

Publications (1)

Publication Number Publication Date
IN2014DN07019A true IN2014DN07019A (en) 2015-04-10

Family

ID=47844410

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7019DEN2014 IN2014DN07019A (en) 2012-01-24 2013-01-22

Country Status (14)

Country Link
US (1) US10254286B2 (en)
EP (1) EP2807485B1 (en)
JP (1) JP6254951B2 (en)
KR (1) KR101716555B1 (en)
CN (1) CN104094116B (en)
AU (2) AU2013213301A1 (en)
BR (1) BR112014018192A8 (en)
CA (1) CA2861437C (en)
ES (1) ES2724232T3 (en)
IL (1) IL233543B (en)
IN (1) IN2014DN07019A (en)
MX (1) MX361058B (en)
RU (1) RU2646498C2 (en)
WO (1) WO2013111054A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2803804B2 (en) 1992-08-21 1998-09-24 株式会社長澤製作所 Button lock
CN115060882A (en) 2009-10-21 2022-09-16 斯克里普斯研究所 Method for detecting rare cells by using non-rare cells
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2015172038A1 (en) * 2014-05-09 2015-11-12 The Scripps Research Institute Compositions and methods for fluid biopsy of melanoma
WO2015103039A1 (en) * 2013-12-30 2015-07-09 The Scripps Research Institute Circulating tumor cell diagnostics for lung cancer
EP3100047B1 (en) 2014-01-27 2021-08-11 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
WO2015127008A1 (en) * 2014-02-21 2015-08-27 Epic Sciences, Inc. Methods for analyzing rare circulating cells
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
CA2959072A1 (en) * 2014-08-25 2016-03-03 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
CN113552350B (en) * 2015-04-21 2024-10-11 基因泰克公司 Compositions and methods for prostate cancer analysis
IL290309B2 (en) * 2015-11-06 2024-04-01 Ventana Med Syst Inc Representative diagnostics
KR20170099787A (en) * 2016-02-23 2017-09-01 노을 주식회사 Labeling substance storing patch, tissue diagnostic method using the patch and device using the same
KR102478639B1 (en) 2016-02-23 2022-12-19 노을 주식회사 Labeling substance storing patch, tissue diagnostic method using the patch and device using the same
KR20170099739A (en) 2016-02-23 2017-09-01 노을 주식회사 Contact-type staining-assist patch, manufacturing method thereof and staining method using the patch
KR102406596B1 (en) * 2016-02-23 2022-06-10 노을 주식회사 Circulating tumor cell diagnosis method using the patch and device using the same
US10371610B2 (en) 2016-02-23 2019-08-06 Noul Co., Ltd. Contact-type patch, staining method using the same, and manufacturing method thereof
MA49289A (en) 2017-04-03 2020-02-12 Hoffmann La Roche ANTIBODIES BINDING TO STEAP-1
WO2019005902A1 (en) * 2017-06-27 2019-01-03 Qcdx, Llc Quantitative liquid biopsy diagnostic system and methods
CN107918013A (en) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 The method and kit of K Ras albumen in chemiluminescence Enzyme immunoassay circulating tumor cell
JP7678424B2 (en) 2018-05-10 2025-05-16 学校法人順天堂 Image analysis method, device, computer program, and method for generating deep learning algorithm
WO2020086882A1 (en) * 2018-10-24 2020-04-30 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
JP7381003B2 (en) * 2019-04-26 2023-11-15 学校法人順天堂 METHODS, APPARATUS AND COMPUTER PROGRAMS TO ASSIST DISEASE ANALYSIS AND METHODS, APPARATUS AND PROGRAMS FOR TRAINING COMPUTER ALGORITHM
WO2023107566A1 (en) 2021-12-07 2023-06-15 Epic Sciences, Inc. Enhanced characterization of breast cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
ES2332435T3 (en) 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited VECTOR DIRECTED TO TUMORS.
JP2003515323A (en) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド Body
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7305112B2 (en) 2002-10-15 2007-12-04 The Scripps Research Institute Method of converting rare cell scanner image coordinates to microscope coordinates using reticle marks on a sample media
GT200500255A (en) * 2004-09-10 2006-04-10 ANTI-5TA HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5TA ANTIBODY / CALICHEAMICINA
EP1984030B1 (en) 2006-01-30 2013-05-08 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
ES2712942T3 (en) 2006-03-10 2019-05-16 Wyeth Llc Anti-5T4 antibodies and uses thereof
WO2008131035A2 (en) 2007-04-16 2008-10-30 Cellpoint Diagnotics, Inc. Methods for diagnosing, prognosing, or theranosing a condition using rare cells
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
CN110470835A (en) 2009-03-24 2019-11-19 生物概念股份有限公司 The device and method of cell capture and analysis
CA2754610C (en) 2009-03-27 2015-05-05 Marc Isaac Damelin Tumor-initiating cells and methods for using same
JP2013504064A (en) 2009-09-03 2013-02-04 ザ スクリプス リサーチ インスティチュート How to classify circulating tumor cells
CN115060882A (en) 2009-10-21 2022-09-16 斯克里普斯研究所 Method for detecting rare cells by using non-rare cells
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
CA2804269A1 (en) 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
CN105288644A (en) 2011-04-01 2016-02-03 惠氏有限责任公司 Antibody-drug conjugates

Also Published As

Publication number Publication date
WO2013111054A1 (en) 2013-08-01
JP6254951B2 (en) 2017-12-27
MX361058B (en) 2018-11-23
RU2014127474A (en) 2016-03-20
AU2018220154A1 (en) 2018-09-13
BR112014018192A8 (en) 2021-03-02
RU2646498C2 (en) 2018-03-05
HK1202923A1 (en) 2015-10-09
IL233543A0 (en) 2014-08-31
CN104094116B (en) 2017-05-31
US20150017661A1 (en) 2015-01-15
ES2724232T3 (en) 2019-09-09
AU2013213301A1 (en) 2014-07-17
CA2861437A1 (en) 2013-08-01
KR101716555B1 (en) 2017-03-14
US10254286B2 (en) 2019-04-09
EP2807485B1 (en) 2019-03-13
IL233543B (en) 2018-02-28
JP2015507190A (en) 2015-03-05
KR20140100580A (en) 2014-08-14
EP2807485A1 (en) 2014-12-03
MX2014008928A (en) 2014-10-24
CN104094116A (en) 2014-10-08
CA2861437C (en) 2018-08-21

Similar Documents

Publication Publication Date Title
IN2014DN07019A (en)
IL225646A0 (en) Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents
MX2013000917A (en) Methods of detecting diseases or conditions using phagocytic cells.
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
EP2524059A4 (en) Detection of gastrointestinal disorders
MX2013002084A (en) Biomarkers and methods of treatment.
GB2519906A (en) Methods and systems for detecting biological components
MY197809A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
WO2013138522A3 (en) Methods for assessing effectiveness and monitoring oncolytic virus treatment
PH12014500063A1 (en) Methods and nucleic acids for determining the prognosis of a cancer subject
GB2531881A (en) Method of isolating circulating tumor cells
GB201015765D0 (en) Use of myeloid cell biomarkers for the diagnosis of cancer
MX2016012697A (en) Protein biomarker profiles for detecting colorectal tumors.
WO2012135844A3 (en) Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
WO2013036543A3 (en) Molecular imaging of cancer cells in vivo
EP2833149A4 (en) Method for detecting degree of malignancy of circulating tumor cell unit, and kit for same
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
NZ629555A (en) Monocyte biomarkers for cancer detection
WO2012012694A3 (en) Methods of detecting autoimmune or immune-related diseases or conditions
EP3385717A3 (en) Methods of detecting prostate cancer
MA40636A (en) Methods of detecting prostate cancer
WO2013081645A3 (en) Erbb3 mutations in cancer
EP2855705A4 (en) METHOD OF DIAGNOSING CANCER COMPRISING THE DETECTION OF THE METHYLATION SIGNATURE IN THE HTERT PROMOTER